Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | KDM5A | P29375 | 1/20 | 0.47 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
| ▸ | NMT1 | P30419 | 3/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.45 |
| ▸ | NMT2 | O60551 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11001459 | 0.86 | KMT2A (0.55) | MEN1KMT2APKMMAPK1MAPT | |
| SCHEMBL393627 | 0.83 | KMT2A (0.63) | MEN1KMT2APKMMAPK1MAPT | |
| SCHEMBL29366579 | 0.83 | KMT2A (0.63) | MEN1KMT2APKMMAPK1MAPT | |
| SCHEMBL11405359 | 0.82 | MAPK1 (0.44) | MEN1KMT2APKMMAPK1KDM5A | |
| SCHEMBL6200293 | 0.81 | MAPK1 (0.55) | MEN1KMT2APKMMAPK1MAPT | |
| SCHEMBL1467161 | 0.81 | MAPK1 (0.65) | MEN1KMT2AMAPK1MAPTALDH1A1 | |
| SCHEMBL11066821 | 0.80 | MEN1 (0.51) | MEN1KMT2APKMMAPK1MAPT | |
| SCHEMBL13544937 | 0.79 | KDM4E (0.41) | MEN1KMT2AMAPTKDM4EPOLB | |
| SCHEMBL618410 | 0.78 | MAPT (0.62) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL1616605 | 0.78 | MAPK1 (0.53) | MEN1KMT2APKMMAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748612-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-10 | — | — | US | disclosed |
| EP-2201010-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2013-11-06 | — | — | EP | disclosed |
| US-20130178496-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2013-07-11 | — | — | US | disclosed |
| US-8410132-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-02 | — | — | US | disclosed |
| US-20130018070-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-17 | — | — | US | disclosed |
| US-8188283-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100261750-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-14 | — | — | US | disclosed |
| EP-2201010-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009036412-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-19 | — | — | WO | disclosed |
| EP-1075478-B1 | PHENYLUREA AND PHENYLTHIO UREA DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2003-04-16 | — | — | EP | disclosed |
| US-6372757-B1 | OREXIN RECEPTORS FOR SLEEP DISORDERS AND EATING DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-04-16 | — | — | US | disclosed |
| EP-1075478-A1 | PHENYLUREA AND PHENYLTHIO UREA DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2001-02-14 | — | — | EP | disclosed |
| WO-1999058533-A1 | PHENYLUREA AND PHENYLTHIO UREA DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1999-11-18 | — | — | WO | disclosed |
| US-4560689-A | ANTICONVULSANTS, ANTIDEPRESSANTS, SEDATIVE ANTIDOTES, AND ANTIEPLILEPTIC AGENTS | CIBA-GEIGY CORPORATION (US) | 1985-12-24 | — | — | US | disclosed |
| US-4479955-A | ANTICONVULSANTS, ANTIDEPRESSANTS, ANTIEPILEPTIC AGENTS | CIBA-GEIGY CORPORATION (US) | 1984-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178496-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, ABCB1, ABCC1 | MEN1 4750/4885KMT2A 4440/4885PKM 2748/4885 |
| US-20130018070-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, ABCB1, ABCC1 | MEN1 4750/4885KMT2A 4440/4885PKM 2748/4885 |
| US-20100261750-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | CFTR, ABCB1, ABCC1 | MEN1 4750/4885KMT2A 4440/4885PKM 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.